Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dalfampridine
Drug ID BADD_D00574
Description Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Indications and Usage Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
Marketing Status Prescription
ATC Code N07XX07
DrugBank ID DB06637
KEGG ID D04127
MeSH ID D015761
PubChem ID 1727
TTD Drug ID D08YIN
NDC Product Code 38779-3205; 42571-338; 63190-0510; 46016-5042; 16729-292; 56125-427; 62756-429; 0054-0479; 42571-275; 51927-5030; 12817-054; 54382-125; 62756-038; 63190-0530; 51407-246; 65862-917; 65372-1157; 65862-863; 62991-3143; 67877-444; 10144-427; 0378-0509
Synonyms 4-Aminopyridine | 4 Aminopyridine | Dalfampridine | Pymadine | VMI-103 | VMI 103 | VMI103 | 4-Aminopyridine Sustained Release | 4 Aminopyridine Sustained Release | Sustained Release, 4-Aminopyridine | Fampridine-SR | Fampridine SR
Chemical Information
Molecular Formula C5H6N2
CAS Registry Number 504-24-5
SMILES C1=CN=CC=C1N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemoglobin urine present13.13.02.0250.013072%Not Available
Laboratory test interference13.18.01.0080.003921%Not Available
Mean cell haemoglobin decreased13.01.05.0050.002614%Not Available
Mean cell volume decreased13.01.05.0270.002614%Not Available
Nuclear magnetic resonance imaging abnormal13.18.03.0030.003921%Not Available
Obstructive uropathy20.01.05.0040.002614%Not Available
Pancreatic cyst16.05.01.005; 07.18.03.0030.002614%Not Available
PCO2 decreased13.02.01.0290.002614%Not Available
Simple partial seizures17.12.05.0010.002614%Not Available
Spinal column stenosis17.10.01.011; 15.10.04.0030.003921%Not Available
Urinary tract infection enterococcal20.08.02.007; 11.02.08.0030.009150%Not Available
Vitamin B12 increased13.02.05.0130.015686%Not Available
Fractured coccyx15.08.05.005; 12.04.04.0050.002614%Not Available
Lumbar vertebral fracture15.08.05.007; 12.04.04.0070.002614%Not Available
Creatinine urine increased13.13.01.0280.003921%Not Available
Transferrin saturation decreased13.11.01.0510.005229%Not Available
Urine leukocyte esterase positive13.13.02.0270.033986%Not Available
Nitrite urine present13.13.02.0260.010457%Not Available
Citrobacter infection11.02.01.0360.001023%Not Available
Lymphocyte percentage decreased13.01.06.0540.009150%Not Available
Lymphocyte percentage increased13.01.06.0550.002614%Not Available
Impaired self-care19.01.02.014; 08.01.03.0710.005229%Not Available
Fracture displacement12.04.02.016; 15.08.02.0130.002614%Not Available
Progressive multiple sclerosis17.16.01.0060.000682%Not Available
Urinary tract infection bacterial20.08.02.006; 11.02.01.0240.009150%Not Available
Enterococcal sepsis11.02.08.0050.000682%Not Available
Clostridium difficile infection11.02.02.0090.003921%Not Available
T-lymphocyte count increased13.01.06.0610.014379%Not Available
Factor V Leiden mutation03.15.01.008; 01.01.02.0190.002614%Not Available
Haemorrhagic cyst24.07.01.069; 16.02.02.013; 08.03.05.0080.002614%Not Available
The 19th Page    First    Pre   19 20    Next   Last    Total 20 Pages